Tyra Biosciences opened lower at $20.67, compared with its previous close of $20.97. In the last trading session, the stock traded between $19.66 and $21.43. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Tyra Biosciences is now worth
$ 70.09
Resulting in a loss of
$ 29.91 (29.91%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.19 (-5.67%)
Day High
$21.43
Day Low
$19.66
Day Open
$20.67
Prev Close
$20.97
Volume
7,04,714
1W Return
-8.04%
1M Return
0.87%
3M Return
-21.39%
6M Return
-41.84%
1Y Return
30.73%
Fundamentals
Market Cap ($ Mn)
1,366
PE Ratio
-
PB Ratio
4.21
PEG Ratio
-
ROE
-39.76%
ROCE
-43.21%
EPS (TTM)
$-0.74
Investment Returns
1 Week
-8.04%
1 Month
0.87%
3 Months
-21.39%
6 Months
-41.84%
9 Months
-34.07%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
Wedbush raises Tyra Biosciences price target to $57, keeps Outperform
Wedbush maintains Outperform rating on Tyra Biosciences. Price target raised from $53 to $57. Analyst Robert Driscoll issued the updated recommendation.
Yesterday
11Nov
HC Wainwright maintains Buy on Tyra Biosciences, cuts target to $27
HC Wainwright & Co. maintains a Buy rating on Tyra Biosciences. Price target lowered from $29 to $27 by analyst Mitchell S. Kapoor. Rating action reflects updated valuation metrics for the company.
Yesterday
14Oct
Pomerantz investigates Tyra Biosciences over securities fraud claims
Pomerantz LLP is investigating Tyra Biosciences for potential securities fraud. Share price fell **17.66%** to **$22.01** after Phase 2 trial data release. Initial SURF302 study showed Grade 3 adverse events in **14%** and **9%** of cohorts. Investigation targets whether officers engaged in unlawful business practices.
1mo ago
30Sep
Pomerantz investigates Tyra Biosciences over securities fraud claims
Pomerantz LLP investigates Tyra Biosciences for securities fraud. Stock fell 17.66% to $22.01 after Phase 2 safety data release. Grade 3 adverse events occurred in 14% and 9% of dose cohorts.
1mo ago
14Sep
Tyra Biosciences prices $400m equity offering at $22.03 per unit
Tyra Biosciences prices offering of 9,079,000 shares at $22.03 per unit. Gross proceeds expected to be approximately $400.0 million. Funds to advance dabogratinib development in LG-UTUC and IR NMIBC. Offering led by RA Capital Management with institutional participation.
1mo ago
14Sep
Tyra Biosciences files shelf prospectus to sell mixed securities
Tyra Biosciences filed a shelf prospectus for mixed securities. Instruments include common stock, preferred stock, debt, warrants, units. No specific offering amount was disclosed in the filing. Future offerings will be detailed in separate prospectus supplements.
